-
top journals such as Journal of Hematology & Oncology (2024), Cancer Research (2024), Cell (2023), Cell Stem Cell (2023 ×2), and Nature Cell Biology (2022). The Su research program is currently
-
) development of small molecule drugs and PROTAC-drug conjugates. The Li group conducts the most forefront science and is highly productive with publications in high-impact journals in the past five years, Nature
-
Medicine, and member of the City of Hope Comprehensive Cancer. The Perry laboratory uses structural biology approaches, together with small molecule and fragment-based drug discovery, computer-aided drug
-
solid cancers. We are especially interested in therapeutic strategies that exploit mitochondrial vulnerabilities, including the use of nucleoside analogs, small GTPase inhibitors, natural plant-derived
-
Oncology, JNCI, Clinical Cancer Research, Nature Communications, Nature Reviews Gastroenterology and Hepatology, Annals of Surgery, etc. If you are passionate about some of the following things we
-
deciphering their underlying molecular mechanisms in normal developmental processes and tumorigenesis. We cover research areas with relevance to RNA Biology, Cancer Biology, Chromatin Regulation, Cancer
-
of transplants, and single-cell and spatial multi-omics. Our research has been published in esteemed journals such as Science, Nature Medicine, Nature Cell Biology, Cell Metabolism, and the Journal of Clinical
-
medical oncology is preferred · A solid understanding of statistical methods and clinical and translational research procedures. · Proficient in written and spoken English City of Hope
-
, natural plant extracts, and immunotherapies. As a successful candidate you will: · Lead projects by designing and performing experimental procedures · Manage data, analyze, and report
-
epitope selection pipelines. · Experience in molecular virology methods, and antigen presentation and processing as applied to human and murine oncology. · Ability to independently document